Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220659934> ?p ?o ?g. }
- W4220659934 endingPage "154034" @default.
- W4220659934 startingPage "154034" @default.
- W4220659934 abstract "As a leading cause of death and disability, alternative therapies for stroke are still limited by its complicated pathophysiological manifestations. Guhong injection (GHI), consisting of safflower aqueous extract and aceglutamide, has been widely applied for the clinical treatment of cerebrovascular diseases, especially ischemic stroke and post-stroke recovery, in China. Recently, a series of studies have reported the positive effect of GHI against cerebral ischemia/reperfusion injury via targeting various molecular mechanisms. However, questions remain on whether treatment with GHI contributes to better functional recovery after stroke and if so, the potential mechanisms and active substances.The aim of this work was to explore the potential therapeutic possibilities of GHI for the neurological and behavioral recovery after stroke and to investigate the underlying molecular mechanisms as well as active substances.The neural and motor deficits as well as cortical lesions after GHI treatment were investigated in a mouse model of transient ischemic stroke. Based on the substance identification of GHI, network pharmacology combined with an experimental verification method was used to systematically decipher the biological processes and signaling pathways closely related to GHI intervention in response to post-stroke functional outcomes. Subsequently, ingenuity pathway analysis (IPA) analysis was performed to determine the anti-stroke active substances targeting to the hub targets involved in the significant molecular pathways regulated by GHI treatment.Therapeutically, administration of GHI observably ameliorated the post-stroke recovery of neural and locomotor function as well as reduced infarct volume and histopathological damage to the cerebral cortex in subacute stroke mice. According to 26 identified or tentatively characterized substances in GHI, the compound-target-pathway network was built. Bioinformatics analysis suggested that inflammatory and apoptotic pathways were tightly associated with the anti-stroke effect of GHI. Based on protein-protein interaction network analysis, the hub targets (such as NF-κB p65, TNF-α, IL-6, IL-1β, Bax, Bcl-2, and Caspase-3) involved in inflammation and apoptosis were selected. On the one hand, immunofluorescence and ELISA results showed that GHI (10 ml/kg) treatment obviously reduced NF-κB p65 nuclear translocation as well as decreased the abnormally elevated concentrations of proinflammatory cytokines (TNF-α, IL-6, and IL-1β) in damaged cortex tissues. On the other hand, GHI (10 ml/kg) treatment significantly downregulated the number of TUNEL-positive apoptotic cells in ischemic cortex and effectively restored the abnormal expression of Bax, Bcl-2, and Caspase-3. Based on the results of IPA, hydroxysafflor yellow A, baicalin, scutellarin, gallic acid, syringin, chlorogenic acid, kaempferol, kaempferol-3-O-β-rutinoside, and rutin acted synergistically on core targets, which could be considered as the active substances of GHI.Overall, the current findings showed that the beneficial action of GHI on improving post-stroke functional recovery of subacute stroke mice partly via the modulation of cortical inflammation and apoptosis. These findings not only provide a reliable reference for the clinical application of GHI, but also shed light on a promising alternative therapeutic strategy for ischemic stroke patients." @default.
- W4220659934 created "2022-04-03" @default.
- W4220659934 creator A5000266360 @default.
- W4220659934 creator A5002554718 @default.
- W4220659934 creator A5044592656 @default.
- W4220659934 creator A5044788727 @default.
- W4220659934 creator A5051491654 @default.
- W4220659934 creator A5063667378 @default.
- W4220659934 creator A5068473447 @default.
- W4220659934 creator A5069298618 @default.
- W4220659934 creator A5069417262 @default.
- W4220659934 creator A5086016811 @default.
- W4220659934 date "2022-05-01" @default.
- W4220659934 modified "2023-10-12" @default.
- W4220659934 title "Guhong injection promotes post-stroke functional recovery via attenuating cortical inflammation and apoptosis in subacute stage of ischemic stroke" @default.
- W4220659934 cites W1503832746 @default.
- W4220659934 cites W182384715 @default.
- W4220659934 cites W2004872316 @default.
- W4220659934 cites W2014572524 @default.
- W4220659934 cites W2017171906 @default.
- W4220659934 cites W2022616380 @default.
- W4220659934 cites W2033591223 @default.
- W4220659934 cites W2033602484 @default.
- W4220659934 cites W2037382204 @default.
- W4220659934 cites W2041471383 @default.
- W4220659934 cites W2066189463 @default.
- W4220659934 cites W2103912979 @default.
- W4220659934 cites W2124679671 @default.
- W4220659934 cites W2133465414 @default.
- W4220659934 cites W2168938595 @default.
- W4220659934 cites W2169589032 @default.
- W4220659934 cites W2325707043 @default.
- W4220659934 cites W2362265365 @default.
- W4220659934 cites W2474747771 @default.
- W4220659934 cites W2520221904 @default.
- W4220659934 cites W2526267187 @default.
- W4220659934 cites W2531529425 @default.
- W4220659934 cites W2537679995 @default.
- W4220659934 cites W2559433778 @default.
- W4220659934 cites W2600153465 @default.
- W4220659934 cites W2606004110 @default.
- W4220659934 cites W2720897370 @default.
- W4220659934 cites W2747892221 @default.
- W4220659934 cites W2789047449 @default.
- W4220659934 cites W2789136063 @default.
- W4220659934 cites W2790520314 @default.
- W4220659934 cites W2792146494 @default.
- W4220659934 cites W2794215220 @default.
- W4220659934 cites W2801780122 @default.
- W4220659934 cites W2807816203 @default.
- W4220659934 cites W2809206621 @default.
- W4220659934 cites W2891793399 @default.
- W4220659934 cites W2895023817 @default.
- W4220659934 cites W2898468989 @default.
- W4220659934 cites W2900430109 @default.
- W4220659934 cites W2902715987 @default.
- W4220659934 cites W2904244708 @default.
- W4220659934 cites W2913876336 @default.
- W4220659934 cites W2914649427 @default.
- W4220659934 cites W2923363662 @default.
- W4220659934 cites W2925683344 @default.
- W4220659934 cites W2949122321 @default.
- W4220659934 cites W2949222823 @default.
- W4220659934 cites W2959218190 @default.
- W4220659934 cites W2966224231 @default.
- W4220659934 cites W2981720404 @default.
- W4220659934 cites W2990786443 @default.
- W4220659934 cites W3000131234 @default.
- W4220659934 cites W3004429638 @default.
- W4220659934 cites W3022109193 @default.
- W4220659934 cites W3025791662 @default.
- W4220659934 cites W3090585812 @default.
- W4220659934 cites W3093194543 @default.
- W4220659934 cites W3093285665 @default.
- W4220659934 cites W3097256238 @default.
- W4220659934 cites W3101755702 @default.
- W4220659934 cites W3102186449 @default.
- W4220659934 cites W3111733449 @default.
- W4220659934 cites W3157584712 @default.
- W4220659934 cites W3198748779 @default.
- W4220659934 cites W3209409000 @default.
- W4220659934 cites W4211073154 @default.
- W4220659934 doi "https://doi.org/10.1016/j.phymed.2022.154034" @default.
- W4220659934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35276592" @default.
- W4220659934 hasPublicationYear "2022" @default.
- W4220659934 type Work @default.
- W4220659934 citedByCount "13" @default.
- W4220659934 countsByYear W42206599342022 @default.
- W4220659934 countsByYear W42206599342023 @default.
- W4220659934 crossrefType "journal-article" @default.
- W4220659934 hasAuthorship W4220659934A5000266360 @default.
- W4220659934 hasAuthorship W4220659934A5002554718 @default.
- W4220659934 hasAuthorship W4220659934A5044592656 @default.
- W4220659934 hasAuthorship W4220659934A5044788727 @default.
- W4220659934 hasAuthorship W4220659934A5051491654 @default.
- W4220659934 hasAuthorship W4220659934A5063667378 @default.
- W4220659934 hasAuthorship W4220659934A5068473447 @default.
- W4220659934 hasAuthorship W4220659934A5069298618 @default.